SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.

Szczegóły
Abstrakt

Tytuł:: SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.
Autorzy:: Walker SN; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Chokkalingam N; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Reuschel EL; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Purwar M; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Xu Z; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Gary EN; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Kim KY; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Helble M; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Schultheis K; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.
Walters J; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.
Ramos S; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.
Muthumani K; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Smith TRF; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.
Broderick KE; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.
Tebas P; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Patel A; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Weiner DB; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.
Kulp DW; Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA .; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Źródło:: Journal of clinical microbiology [J Clin Microbiol] 2020 Oct 21; Vol. 58 (11). Date of Electronic Publication: 2020 Oct 21 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Washington, American Society for Microbiology.
MeSH Terms:: Clinical Laboratory Techniques*
Antibodies, Blocking/*blood
Betacoronavirus/*immunology
Coronavirus Infections/*diagnosis
Peptidyl-Dipeptidase A/*immunology
Pneumonia, Viral/*diagnosis
Angiotensin-Converting Enzyme 2 ; Animals ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Betacoronavirus/isolation & purification ; COVID-19 ; COVID-19 Testing ; COVID-19 Vaccines ; Coronavirus Infections/blood ; Coronavirus Infections/immunology ; Coronavirus Infections/prevention & control ; Enzyme-Linked Immunosorbent Assay ; Guinea Pigs ; Humans ; Immunoglobulin G/blood ; Mice ; Neutralization Tests ; Pandemics ; Pneumonia, Viral/blood ; Pneumonia, Viral/immunology ; Primates ; Rabbits ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/immunology ; Surface Plasmon Resonance ; Viral Vaccines/administration & dosage ; Viral Vaccines/immunology
References:: Nat Med. 2020 Sep;26(9):1422-1427. (PMID: 32651581)
Nat Commun. 2020 May 4;11(1):2251. (PMID: 32366817)
J Med Virol. 2005 Oct;77(2):147-50. (PMID: 16121363)
JAMA. 2020 Apr 28;323(16):1582-1589. (PMID: 32219428)
J Virol. 2020 Mar 17;94(7):. (PMID: 31996437)
Analyst. 2020 Jun 7;145(11):3776-3800. (PMID: 32374303)
Nat Commun. 2020 May 20;11(1):2601. (PMID: 32433465)
Transfus Med. 2021 Jun;31(3):167-175. (PMID: 33333627)
Science. 2020 Jun 5;368(6495):1060-1061. (PMID: 32414781)
Nature. 2020 May;581(7807):215-220. (PMID: 32225176)
Immunity. 2020 Apr 14;52(4):583-589. (PMID: 32259480)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
J Infect Dis. 2005 Mar 1;191(5):755-60. (PMID: 15688292)
Curr Trop Med Rep. 2020;7(2):61-64. (PMID: 32219057)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307. (PMID: 32074516)
Nature. 2003 Nov 27;426(6965):450-4. (PMID: 14647384)
Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64. (PMID: 14651994)
Science. 2020 Aug 7;369(6504):731-736. (PMID: 32540900)
Science. 2020 May 1;368(6490):489-493. (PMID: 32179701)
Nature. 2020 May;581(7807):221-224. (PMID: 32225175)
Cell Rep Med. 2021 Oct 19;2(10):100420. (PMID: 34604818)
Hypertension. 2004 Dec;44(6):903-6. (PMID: 15492138)
Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
Science. 2020 Jun 12;368(6496):1274-1278. (PMID: 32404477)
Cell Mol Immunol. 2020 Jun;17(6):613-620. (PMID: 32203189)
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318)
Science. 2020 Mar 27;367(6485):1444-1448. (PMID: 32132184)
Emerg Microbes Infect. 2020 Dec;9(1):680-686. (PMID: 32207377)
Signal Transduct Target Ther. 2020 Dec 4;5(1):283. (PMID: 33277466)
Grant Information:: T32 CA009171 United States CA NCI NIH HHS
Contributed Indexing:: Keywords: ACE2 blocking assay; COVID-19; SARS-CoV-2; SARS-CoV-2 immunity; SARS-CoV-2 vaccine; functional antibodies; serological tests
Substance Nomenclature:: 0 (Antibodies, Blocking)
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (COVID-19 Vaccines)
0 (Immunoglobulin G)
0 (Spike Glycoprotein, Coronavirus)
0 (Viral Vaccines)
0 (spike protein, SARS-CoV-2)
EC 3.4.15.1 (Peptidyl-Dipeptidase A)
EC 3.4.17.23 (ACE2 protein, human)
EC 3.4.17.23 (Ace2 protein, mouse)
EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
Entry Date(s):: Date Created: 20200829 Date Completed: 20201104 Latest Revision: 20240330
Update Code:: 20240330
PubMed Central ID:: PMC7587116
DOI:: 10.1128/JCM.01533-20
PMID:: 32855181
: Czasopismo naukowe

S evere a cute r espiratory s yndrome co rona v irus 2 (SARS-CoV-2) has caused a global pandemic of COVID-19, resulting in cases of mild to severe respiratory distress and significant mortality. The global outbreak of this novel coronavirus has now infected >20 million people worldwide, with >5 million cases in the United States (11 August 2020). The development of diagnostic and research tools to determine infection and vaccine efficacy is critically needed. We have developed multiple serologic assays using newly designed SARS-CoV-2 reagents for detecting the presence of receptor-binding antibodies in sera. The first assay is surface plasmon resonance (SPR) based and can quantitate both antibody binding to the SARS-CoV-2 spike protein and blocking to the Angiotensin-converting enzyme 2 (ACE2) receptor in a single experiment. The second assay is enzyme-linked immunosorbent assay (ELISA) based and can measure competition and blocking of the ACE2 receptor to the SARS-CoV-2 spike protein with antispike antibodies. The assay is highly versatile, and we demonstrate the broad utility of the assay by measuring antibody functionality of sera from small animals and nonhuman primates immunized with an experimental SARS-CoV-2 vaccine. In addition, we employ the assay to measure receptor blocking of sera from SARS-CoV-2-infected patients. The assay is shown to correlate with pseudovirus neutralization titers. This type of rapid, surrogate neutralization diagnostic can be employed widely to help study SARS-CoV-2 infection and assess the efficacy of vaccines.
(Copyright © 2020 American Society for Microbiology.)

Informacja